TransMedics Group, Inc.
TMDXHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeHeadquartered within the healthcare sector, TransMedics Group, Inc. focuses on Medical Devices services and products. TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company carries a $2.32B market cap, placing it firmly in the mid-cap category. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Market Cap
$2.32B
Beta
2.06
P/E (TTM)
15.38
P/E (Fwd)
18.91
EPS (TTM)
$4.37
EPS (Fwd)
$3.55
ROE
45.2%
ROA
5.2%
Cash
$461.7M
Total Debt
$863.4M
Free CF
$108.8M
52W Change
-45.8%
Annual Financials
Cash vs Debt
TransMedics Group, Inc. carries $863.4M in total debt against $461.7M in cash reserves — debt is roughly 1.9x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $108.8M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 45.2%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.2% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $93.5M (2022) to $605.5M (2025), reflecting a 548% increase over the period.
TransMedics Group, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence TransMedics Group, Inc.'s trajectory.